High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells.

Cannabis extract IL-6 IL-8 miR-302c-3p miR-760

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 01 09 2022
revised: 26 07 2023
accepted: 28 07 2023
medline: 4 9 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

The incidence of chronic inflammatory disorders and autoimmune diseases is rapidly growing. To date, the COVID-19 pandemic caused by SARS-CoV-2 has killed over 6,209,000 people globally, while no drug has been proven effective for the disease. Screening natural anti-inflammatory compounds for clinical application has drawn much attention. In this study, we showed that high-CBD cannabis extracts #1, #5, #7, #169, and #317 suppressed the levels of expression of proinflammatory cyclooxygenase 2 (COX2) and increased the expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human small intestinal epithelial cells (HSIEC) in TNFα/IFNγ-triggered inflammation. We revealed that these extracts, with the exception of extract #169, also profoundly attenuated induction of proinflammatory cytokines interleukin-6 (IL-6) and/or IL-8 proteins through miR-760- and miR-302c-3p-mediated silencing. The prevalent components in extracts #1 and #7 influenced the levels of IL-8 both individually as well as in combination with each other. However, the high-dose cannabis extracts displayed an inhibitory effect in the growth of HSIEC cells. These results show that our high-CBD cannabis extracts decrease the levels of proinflammatory molecules COX2, IL-6, and IL-8 via transcriptional suppression or miRNA-mediated silencing, highlighting their potential against COVID-19-associated cytokine storm syndrome.

Identifiants

pubmed: 37664748
doi: 10.1016/j.heliyon.2023.e18817
pii: S2405-8440(23)06025-5
pmc: PMC10468390
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e18817

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following conflict of interests: Pathway Rx and Swysh are biotechnology start-ups involved in medical cannabis, health and disease research and development. Notwithstanding, this had no. bearing on the study design, data analysis and interpretation. O.K., A.F and I.K are co-founders of start-ups, and B.W. and D.L. are team members. All listed authors have filed for the following relevant patents: PCT/IL2021/050265 and USP no. 62/994873. Authors have applied for other patents in medical cannabis field, albeit these are unrelated to the current study.

Références

N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
J Clin Immunol. 2021 Feb;41(2):303-314
pubmed: 33188624
Cancer Res. 2002 Nov 1;62(21):6323-8
pubmed: 12414664
Cochrane Database Syst Rev. 2021 Mar 18;3:CD013881
pubmed: 33734435
F1000Res. 2021 Feb 4;10:73
pubmed: 33763201
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Nat Rev Cancer. 2001 Oct;1(1):11-21
pubmed: 11900248
Aging (Albany NY). 2020 Nov 22;12(22):22425-22444
pubmed: 33221759
Cell Mol Immunol. 2014 Jan;11(1):105-6
pubmed: 24037182
J Cell Mol Med. 2020 Nov;24(21):12869-12872
pubmed: 33058425
OMICS. 2021 Jan;25(1):13-22
pubmed: 32857671
Life Sci. 2019 Nov 15;237:116915
pubmed: 31610207
JAMA Intern Med. 2021 Jan 1;181(1):41-51
pubmed: 33080002
Future Med Chem. 2009 Oct;1(7):1333-49
pubmed: 20191092
Cell Death Discov. 2022 Mar 11;8(1):110
pubmed: 35277472
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Biol Pharm Bull. 2011;34(5):774-8
pubmed: 21532172
Pharmacol Res. 2016 Nov;113(Pt A):199-208
pubmed: 27498155
Sci Rep. 2020 Nov 23;10(1):20405
pubmed: 33230154
Ochsner J. 2021 Summer;21(2):177-180
pubmed: 34239378
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Oncotarget. 2017 Aug 16;8(41):71038-71053
pubmed: 29050341
J Immunol. 2021 Apr 1;206(7):1597-1608
pubmed: 33579725
Asian J Androl. 2021 Jan-Feb;23(1):85-90
pubmed: 32415054
FASEB J. 2004 Jan;18(1):191-3
pubmed: 14597565
Cytokine Growth Factor Rev. 2020 Jun;53:63-65
pubmed: 32467020
Virus Res. 2020 Sep;286:198103
pubmed: 32717345
Med. 2021 Jan 15;2(1):99-112.e7
pubmed: 32838362
J Biol Chem. 2010 Jan 15;285(3):1616-26
pubmed: 19910459
J Immunol. 2012 Oct 1;189(7):3439-48
pubmed: 22925925
Indian J Clin Biochem. 2021 Oct;36(4):440-450
pubmed: 34177139
World J Gastroenterol. 2020 May 21;26(19):2323-2332
pubmed: 32476796
Int J Mol Sci. 2021 Jul 07;22(14):
pubmed: 34298921
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Cell Signal. 2012 Aug;24(8):1658-64
pubmed: 22560881
Cannabis Cannabinoid Res. 2020 Sep 02;5(3):197-201
pubmed: 32923657
Cochrane Database Syst Rev. 2021 Aug 16;8:CD014963
pubmed: 34396514
Sci Rep. 2021 Mar 8;11(1):5434
pubmed: 33686185
Nat Rev Immunol. 2005 May;5(5):400-11
pubmed: 15864274
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
J Ethnopharmacol. 2021 Apr 24;270:113743
pubmed: 33359187
Aging (Albany NY). 2021 Jan 19;13(2):1571-1590
pubmed: 33465050
Immunobiology. 2015 Aug;220(8):947-53
pubmed: 25720636
Mediators Inflamm. 2013;2013:650812
pubmed: 24078776
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Neurosci Lett. 2020 Feb 16;720:134779
pubmed: 31981721
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Signal Transduct Target Ther. 2020 Dec 14;5(1):292
pubmed: 33318472
Pharmacotherapy. 2021 Nov;41(11):884-906
pubmed: 34558742
J Pediatr Gastroenterol Nutr. 2021 Mar 1;72(3):384-387
pubmed: 32969960
Cancer Res. 2015 Sep 15;75(18):3832-41
pubmed: 26199092
Lancet Respir Med. 2020 Dec;8(12):1233-1244
pubmed: 33075298
J Cell Physiol. 2002 Mar;190(3):279-86
pubmed: 11857443
Neurogastroenterol Motil. 2015 Oct;27(10):1432-45
pubmed: 26227635
PLoS One. 2017 Nov 3;12(11):e0187572
pubmed: 29099860
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243
pubmed: 34028504
Genes Dis. 2021 Jul;8(4):385-400
pubmed: 33521210
Theranostics. 2021 Jan 1;11(1):316-329
pubmed: 33391477
Pharmacol Res. 2016 Sep;111:303-315
pubmed: 27343699
J Cell Biochem. 2001;81(4):715-23
pubmed: 11329626
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Clin Infect Dis. 2021 Aug 2;73(3):361-366
pubmed: 32638022
Biomolecules. 2020 Oct 08;10(10):
pubmed: 33049992
Methods Mol Biol. 2014;1172:285-93
pubmed: 24908315
Nat Immunol. 2008 Apr;9(4):353-9
pubmed: 18349815
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
Future Sci OA. 2020 Aug 13;6(8):FSO625
pubmed: 32974048
Int Immunopharmacol. 2020 Jul;84:106556
pubmed: 32416450
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Front Immunol. 2019 May 08;10:1027
pubmed: 31139184
Phytomedicine. 2015 Dec 15;22(14):1262-8
pubmed: 26655409
J Investig Med. 2022 Jan;70(1):55-60
pubmed: 34561232

Auteurs

Bo Wang (B)

Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.
Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.

Dongping Li (D)

Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.
Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.

Anna Fiselier (A)

Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.
Swysh Inc., Calgary, Alberta, T3H 4Z2, Canada.

Igor Kovalchuk (I)

Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.
Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.
Swysh Inc., Calgary, Alberta, T3H 4Z2, Canada.

Olga Kovalchuk (O)

Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.
Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.
Swysh Inc., Calgary, Alberta, T3H 4Z2, Canada.

Classifications MeSH